2026 Q1 Earnings Results IR Meeting


  • Purpose: Announce 2026 Q1 preliminary earnings and R&D session
  • Date/Time: 2026-05-07 10:30, conference call format
  • Participants: Domestic and foreign investors and analysts
  • Presentation materials and live audio webcasting will be posted on the website on the same day.
ADVERTISEMENT (250px+)

KOSPI Filing Information


  • Filing: Corporate Briefing (IR) Holding (Notice Disclosure)
  • Company: SK Biopharmaceuticals (326030)
  • Submission: SK Biopharmaceuticals Co., Ltd.
  • Receipt: 05-04-2026
  • Under KRX KOSPI Market Division